Showing 6891-6900 of 8884 results for "".
- Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluzhttps://practicaldermatology.com/news/biofrontera-inc-announces-fda-filing-of-supplemental-new-drug-application-for-ameluz/2462237/Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has issued a "no filing review issues identified" letter regarding the sNDA (supplementary New Drug Application) submitted
- American Academy of Dermatology Issues Updated Guidelines for the Management of Acnehttps://practicaldermatology.com/news/american-academy-of-dermatology-issues-updated-guidelines-for-the-management-of-acne/2462235/Acne is the most common skin condition in the United States, affecting nearly 50 million Americans each year, with symptoms usually beginning in puberty. Acne affects 85% of adolescents and can also often begin or continue in adulthood, especially in women. To help ensure that
- Analysis: Inconsistent Pretreatment Testing for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/analysis-inconsistent-pretreatment-testing-for-inflammatory-skin-diseases/2462233/A new analysis of US commercial insurance claims databases indicated that less than 60% of people living with chronic inflammatory skin diseases (CISD) receive recommended pretreatment testing.
- Large Registries Leave Data Gaps for Melanoma in Black Patientshttps://practicaldermatology.com/news/large-registries-leave-gaps-in-data-on-melanoma-in-black-patients/2462232/New research published in JAMA Dermatology provides crucial patient-level and tumor-level insights into melanoma in Black patients that has been lacking in large registiries.
- Roflumilast Formulations Show Favorable Tolerability Across Several Trials: Analysishttps://practicaldermatology.com/news/roflumilast-formulations-show-favorable-tolerability-across-several-trials-analysis/2462229/Investigator- and patient-rated assessments indicated that topical roflumilast was tolerable and did not cause discomfort, according to a new analysis of data from several clinical trials.
- Highlights from Maui Derm 2024https://practicaldermatology.com/news/highlights-from-maui-derm-2024/2462227/The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recap
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for